옵션 체인은 다양한 행사가격과 만기일에 대한 Bone Biologics의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Bone Biologics에 대한 시장 심리를 평가합니다..

Bone Biologics (NASDAQ:BBLG) 주식, 옵션 체인

Bone Biologics

Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has applications in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.

Bone Biologics Corp

Chegg, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) shares are down after the company reported its third-quarter results after Tuesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/11/b41918921/chegg-reports-2024-third-quarter-earnings">details from the report. </a>
The Details: Chegg reported quarterly earnings of nine cents per share, which beat the analyst consensus estimate of eight cents. Quarterly revenue came in at $136.59 million, which beat the analyst consensus estimate of $134.11 million and a decrease from sales of $157.85 million from the same period last year.
<ul>
<li>Total net revenues of $136.6 million, a decrease of 13% year-over-year</li>
<li>Subscription Services revenues of $119.8 million, a decrease of 14% year-over-year</li>
<li>Gross Margin of 68%</li>
<li>Non-GAAP gross margin of 70%</li>
<li>Adjusted EBITDA was $22.3 million</li>
<li>3.8 million Subscription Services subscribers, a decrease of 13% year-over-year</li>
</ul>
Chegg announced additional restructuring efforts, effective immediately, to impact all groups across the company:
<ul>
<li>Chegg will reduce headcount by an additional 21%.</li>
<li>Chegg anticipates that these actions, along with additional operating expense savings, will result in annualized non-GAAP cost savings of $60-$70 million in 2025.</li>
<li>The cost savings from the restructuring announced in June, coupled with the restructuring announced today, will result in a combined non-GAAP savings of $100-$120 million in 2025.</li>
</ul>
Read Next: <a href="https://www.benzinga.com/news/earnings/24/11/41914981/bitcoin-miners-hive-digital-hut-8-bitfarms-to-report-earnings-as-future-of-crypto-has-never-been-brighter">Bitcoin Miners Hive Digital, Hut 8, Bitfarms To Report Earnings As Future Of Crypto &#8216;Has Never Been Brighter&#8217;</a>
&#8220;While the global education industry continues to experience tremendous change, in the third quarter, we showed early progress against our strategic plan and delivered better-than-expected revenue and adjusted EBITDA. However, recent technology shifts and generative AI have created significant headwinds, and as a result, we are undertaking an additional restructuring,&#8221; said Nathan Schultz, CEO of Chegg.
&#8220;There continues to be a market of students looking for the high-quality, proven, and differentiated learning expertise Chegg provides, and we believe our brand and product experience are resilient and will endure,&#8221; Schultz added. 
Outlook:&nbsp;Chegg sees fourth-quarter total net revenue of between $141 million and $143 million, versus the $161.46 million estimate and subscription services revenue in a range of $126 million to $128 million with adjusted EBITDA of between $32 million and $34 million. 
CHGG Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Chegg shares are down 14.12% after-hours at $1.52 at the time of publication Tuesday.
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a></li>
</ul>
Photo: Shutterstock

News

Education

Guidance

After-Hours Center

Movers

CHGG

Chegg Stock Slips After Q3 Results, 21% Workforce Reduction, Weak Q4 Guidance

Phoenix New Media (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FENG#NYSE">FENG</a>) .

FENG

Phoenix New Media Expected Q4 2024 revenue: RMB 197.9 - 212.9 million.

Nauticus Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) reported quarterly losses of $(4.24) per share. This is a 72.57 percent increase over losses of $(15.46) per share from the same period last year. The company reported $370.19 thousand in sales this quarter. This is a 76.78 percent decrease over sales of $1.59 million the same period last year.

Earnings

KITT

Nauticus Robotics Q3 EPS $(4.24) Up From $(15.46) YoY, Sales $370.19K Down From $1.59M YoY

SKYX Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYX#NASDAQ">SKYX</a>) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 11.11 percent. This is unchanged from the same period last year. The company reported quarterly sales of $22.17 million which missed the analyst consensus estimate of $23.41 million by 5.30 percent. This is a 2.55 percent increase over sales of $21.62 million the same period last year.

Earnings Beats

Earnings Misses

SKYX

SKYX Platforms Q3 EPS $(0.08) Beats $(0.09) Estimate, Sales $22.17M Miss $23.41M Estimate

KORE

KORE Group Rescheduling The Release Of The Company's Financial Results For Q3 2024 And Live Webcast To Discuss Those Results From Previously Scheduled November 13, 2024 At 5pm ET To November 19, 2024 At The Same Time

Company to restate Second Quarter 2024 Financial Statements No impact to Revenues, Cash Flows or Adjusted EBITDA expected for the period affected
ATLANTA, Nov. 12, 2024 /PRNewswire/ -- KORE Group Holdings, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KORE#NYSE">KORE</a>) ("KORE" or the "Company"), the global pure-play Internet of Things ("IoT") hyperscaler, and provider of IoT Connectivity, Solutions and Analytics announced that it expects to restate its second quarter 2024 financial statements and, as a result, is rescheduling the release of the Company's financial results for the third quarter of 2024 and live webcast to discuss those results from previously scheduled November 13, 2024 at 5PM ET to November 19, 2024 at the same time.
The Company's management, in consultation with the Audit Committee of the Company's Board of Directors and in consultation with BDO USA, P.C., the Company's independent registered public accounting firm, concluded that the Company's previously issued unaudited condensed consolidated financial statements contained within the Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 should no longer be relied upon due to errors in computing a non-cash goodwill impairment charge. The restatement is not expected to have any impact on the Company's revenues, cash flows or Adjusted EBITDA for the period affected.
The Company intends to file a Form 10-Q/A for the quarter ended June 30, 2024, which will include restated unaudited condensed consolidated financial statements by November 19, 2024.

KORE's Previously Issued Unaudited Condensed Consolidated Financial Statements Contained Within The Quarterly Report On Form 10-Q For The Quarter Ended June 30, 2024 Should No Longer Be Relied Upon Due To Errors In Computing A Non-cash Goodwill Impairment Charge; Company To Restate Q2 2024 Financial Statements; No Impact To Revenues, Cash Flows Or Adjusted EBITDA Expected For The Period Affected

Tucker served as CFO of Jack in the Box Inc. from March 2018 to July 2020.

Management

JACK

Jack In The Box Reveals Return Of Lance Tucker As CFO, Effective January 13, 2025; Tucker Served As Its CFO From March 2018 To July 2020

Nuvei (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVEI#NASDAQ">NVEI</a>) reported quarterly earnings of $0.34 per share which missed the analyst consensus estimate of $0.50 by 32 percent. This is a 12.82 percent decrease over earnings of $0.39 per share from the same period last year. The company reported quarterly sales of $357.62 million which beat the analyst consensus estimate of $336.98 million by 6.12 percent. This is a 17.31 percent increase over sales of $304.85 million the same period last year.

NVEI

Nuvei Q3 Adj $0.34 Misses $0.50 Estimate, Sales $357.62M Beat $336.98M Estimate

RISES OVER 1.6% AT IT&#8217;S HIGH FOR THE DAY AFTER EARLY DROP AND THE POWER INFLOW SIGNAL
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="710" height="792" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/12211646/Screen-Shot-2024-11-12-at-4.13.02-PM.png" alt="" class="wp-image-3268" style="width:auto;height:450px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/12211646/Screen-Shot-2024-11-12-at-4.13.02-PM.png 710w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/11/12211646/Screen-Shot-2024-11-12-at-4.13.02-PM-269x300.png 269w" sizes="(max-width: 710px) 100vw, 710px" /></figure>
Eli Lilly &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:35 AM on November 12th, a significant trading signal occurred for Eli Lilly as it demonstrated a Power Inflow at a price of $816.14. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Lilly&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Lilly&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for LLY, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like <a href="https://finitusa.com/en/">Finit USA</a>, responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE:
The price at the time of the Power Inflow was $816.14. The returns on the High price ($829.27) and Close price ($819.57) after the Power Inflow were respectively 1.6% and 0.4%. That is why it is important to have a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite. 
Past Performance is Not Indicative of Future Results

Signals

Markets

Trading Ideas

Tradepulse Power Inflow Alert: Eli Lilly & Company Moves Up Over 13 Points After Signal

Rivian Automotive Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) shares are moving higher in Tuesday&#8217;s after-hours session after the company announced the launch of its <a href="https://www.benzinga.com/pressreleases/24/11/b41919069/faster-leaner-more-efficient-rivian-and-volkswagen-group-announce-the-launch-of-their-joint-ventur">joint venture with Volkswagen Group</a>.
What Happened: Rivian and Volkswagen entered into a transaction agreement to create a new joint venture called &#8220;Rivian and VW Group Technology, LLC.&#8221; The deal has a total value of up to $5.8 billion and is expected to commence on Wednesday.
The joint venture will focus on providing next-generation electrical architecture and software technology for both companies&#8217; future electric vehicles across relevant vehicle segments.
Developers and software engineers from both companies are expected to join the joint venture. Teams will be based in Palo Alto, California, initially, with three other sites in development. Rivian&#8217;s Wassym Bensaid and Volkswagen&#8217;s Carsten Helbing will lead the joint venture as co-CEOs.
&#8220;Today&#8217;s finalization of our joint venture with Volkswagen Group marks an important step forward in helping transition the world to electric vehicles. We&#8217;re thrilled to see our technology being integrated in vehicles outside of Rivian, and we&#8217;re excited for the future,&#8221; said RJ Scaringe, founder and CEO of Rivian. 
Check This Out: <a href="https://www.benzinga.com/tech/24/11/41873064/tesla-rival-rivian-reports-steep-loss-of-about-40k-per-ev-in-q3-as-deliveries-hit-lowest-since-q1-2023">Tesla Rival Rivian Reports Steep Loss Of About $40K Per EV In Q3 As Deliveries Hit Lowest Since Q1 2023</a>
Rivian and Volkswagen expect to reduce development costs and scale new technologies more quickly through the joint venture. The joint venture aims to use existing Rivian architecture and software to enable the launch of Rivian&#8217;s R2 in the first half of 2026. The first models from Volkswagen supported by the joint venture are anticipated as early as 2027. 
Volkswagen has already invested $1 billion in convertible senior notes. The company will invest about $1.3 billion at the closing of the joint venture. Volkswagen plans to invest up to $5.8 billion by 2027.
Rivian is currently discussing the announcement on a <a href="https://rivian-special-call-webcast-2024.open-exchange.net/registration">call</a> with investors that kicked off at 5 p.m. ET. 
RIVN Price Action: Rivian shares were up 9.64% in after-hours, trading at $11.60 at the time of writing Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Courtesy of Rivian.

Contracts

Tech

RIVN

Rivian Stock Races Higher After The Bell: What's Going On?

These collaborations aim to jointly advance plans and the first phase of execution for the development, testing, regulatory compliance, supply chain, and production planning of the two models.

FFIE

Faraday Future Subsidiary Faraday X Signs Definitive Agreements Relating To Two Planned Products With Top Original Equipment Manufacturers

MultiSensor AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSAI#NASDAQ">MSAI</a>) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.02) by 1600 percent. This is a 90.23 percent increase over losses of $(3.48) per share from the same period last year. The company reported $1.60 million in sales this quarter. This is a 6.87 percent increase over sales of $1.50 million the same period last year.

Infrared Cameras Holdings, Inc. - Common Stock

MSAI

MultiSensor AI  Q3 EPS $(0.34) Misses $(0.02) Estimate, Sales $1.60M Up From $1.50M YoY

Orla Mining (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ORLA#AMEX">ORLA</a>) reported quarterly earnings of $0.06 per share which missed the analyst consensus estimate of $0.08 by 25 percent. The company reported quarterly sales of $99.31 million which beat the analyst consensus estimate of $80.39 million by 23.54 percent. This is a 64.70 percent increase over sales of $60.29 million the same period last year.

ORLA

Orla Mining Q3 2024 Adj EPS $0.06 Misses $0.08 Estimate, Sales $99.31M Beat $80.39M Estimate

NRDY

Nerdy Reveals Receipt Of Non-Compliance Notice From NYSE On November 12

Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(0.85) by 23.53 percent. This is a 53.9 percent increase over losses of $(1.41) per share from the same period last year.

CLDI

Calidi Biotherapeutics Q3 2024 GAAP EPS $(0.65) Beats $(0.85) Estimate

Occidental Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) reported its third-quarter results after Tuesday's closing bell. Here's a look at the key <a href="https://www.benzinga.com/pressreleases/24/11/g41919462/occidental-announces-third-quarter-2024-results">figures from the quarter. </a>
The Details:&nbsp;Occidental Petroleum reported quarterly adjusted earnings of $1.00 per share, beating the analyst consensus estimate of 74 cents. Quarterly revenue came in at $7.15 billion, missing the consensus estimate of $7.23 billion. 
<ul>
<li>Strong operational performance drove operating cash flow of $3.8 billion and operating cash flow before working capital of $3.1 billion.</li>
<li>Capital spending of $1.7 billion and contributions from noncontrolling interest of $47 million resulted in quarterly free cash flow before working capital of $1.5 billion.</li>
<li>Total company production of 1,412 Mboed exceeded the mid-point of guidance by 22 Mboed.</li>
<li>Midstream and marketing exceeded the mid-point of guidance for pre-tax adjusted income by $145 million.</li>
<li>OxyChem exceeded guidance with pre-tax income of $304 million.</li>
<li>Repaid $4 billion of debt, achieving nearly 90% of Occidental&#8217;s short-term debt reduction target.</li>
</ul>
Read Next: <a href="https://www.benzinga.com/news/earnings/24/11/41914981/bitcoin-miners-hive-digital-hut-8-bitfarms-to-report-earnings-as-future-of-crypto-has-never-been-brighter">Bitcoin Miners Hive Digital, Hut 8, Bitfarms To Report Earnings As Future Of Crypto &#8216;Has Never Been Brighter&#8217;</a>
&#8220;Strong operational performance across all segments has resulted in our highest quarterly operating cash flow this year,&#8221; said president and CEO Vicki Hollub. 
&#8220;The integration of CrownRock is off to a great start in terms of personnel and operations, and we have made significant progress in our deleveraging efforts, achieving nearly 90% of our short-term debt reduction target,&#8221; Hollub added. 
The company will host a conference call to discuss the results at 1 p.m. ET Wednesday.&nbsp;
OXY Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Occidental Petroleum shares are up 0.52% after-hours at $50.55 at the time of publication Tuesday.
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a></li>
</ul>
Photo: Shutterstock

Commodities

Occidental Petroleum Shares Steady After Mixed Q3 Results

Oriental Culture Holding H1 EPS $(0.28) Up From $(0.50) YoY, Sales $0.447M Down From $0.799M YoY

Aris Mining (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ARMN#AMEX">ARMN</a>) reported quarterly earnings of $0.08 per share which missed the analyst consensus estimate of $0.14 by 42.86 percent. The company reported quarterly sales of $131.577 million which missed the analyst consensus estimate of $138.440 million by 4.96 percent. This is a 16.49 percent increase over sales of $112.955 million the same period last year.

ARMN

Aris Mining Q3 2024 Adj. EPS $0.08 Misses $0.14 Estimate, Sales $131.577M Miss $138.440M Estimate

Bolt Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLT#NASDAQ">BOLT</a>) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.35) by 14.29 percent. The company reported quarterly sales of $1.141 million which missed the analyst consensus estimate of $1.263 million by 9.64 percent. This is a 54.87 percent decrease over sales of $2.528 million the same period last year.

BOLT

Bolt Biotherapeutics Q3 2024 GAAP EPS $(0.40) Misses $(0.35) Estimate, Sales $1.141M Miss $1.263M Estimate

TERN

Terns Pharma Q3 EPS $(0.28) Beats $(0.34) Estimate

Bone Biologics Corp (BBLG) stock has risen 2.99% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator. Bone Biologics Corp has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on BBLG!See Full BBLG ReportWhat is Stock Sentiment?Sentiment is a

Should You Buy Bone Biologics Corp (BBLG) Stock After it Is Up 2.99% in a Week?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Bone Biologics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bblg-stock-quote/">BBLG</a>) just reported results for the first quarter of 2024.<ul><li>Bone Biologics reported earnings per share of -$1.31. This was above the analyst estimate for EPS of -$7.60.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/bblg-stock-earnings-bone-biologics-for-q1-of-2024/">BBLG Stock Earnings: Bone Biologics Beats EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BBLG Stock Earnings: Bone Biologics Beats EPS for Q1 2024

Novavax, Capricor Therapeutics, Arcutis Biotherapeutics among healthcare movers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out as we dive into all of the biggest ones worth watching on Wednesday morning!



Moving stocks are new deals and contracts, earnings reports, stock offerings and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Actelis Networks (NASDAQ:<a href="https://investorplace.com/stock-quotes/asns-stock-quote/">ASNS</a>) stock is rocketing more than 821% on a deal to <a href="https://www.nasdaq.com/press-release/actelis-receives-new-orders-supply-three-military-bases-cyber-hardened-networking">supply technology to three military bases</a>.</li>



<li>MF International (NASDAQ:<a href="https://investorplace.com/stock-quotes/mfi-stock-quote/">MFI</a>) shares are soaring over 139% with heavy trading roughly <a href="https://www.marketwatch.com/story/mf-international-shares-more-than-double-in-trading-debut-after-ipo-607bbac5">one month after its public debut</a>.</li>



<li>ENDRA Life Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/ndra-stock-quote/">NDRA</a>) stock is surging more than 63% after falling yesterday on an <a href="https://www.investing.com/news/company-news/endra-life-sciences-sets-8-million-stock-offering-93CH-3470094">$8 million stock offering</a>.</li>



<li>WalkMe (NASDAQ:<a href="https://investorplace.com/stock-quotes/wkme-stock-quote/">WKME</a>) shares are gaining over 43% on a <a href="https://seekingalpha.com/news/4112995-walkme-stock-leaps-after-15b-takeover-deal-with-sap?source=content_type%3Areact%7Cfirst_level_url%3Amarket-news%7Csection_asset%3Amain">$1.5 billion takeover deal</a>.</li>



<li>Concord Medical Services (NYSE:<a href="https://investorplace.com/stock-quotes/ccm-stock-quote/">CCM</a>) stock is rising more than 33% with strong early morning trading.</li>



<li>Moving iMage Technologies (NYSEMKT:<a href="https://investorplace.com/stock-quotes/mitq-stock-quote/">MITQ</a>) shares are increasing over 25% after being <a href="https://www.nasdaq.com/press-release/moving-image-technologies-mit-awarded-multi-million-dollar-contract-state-art-alamo">granted a new contract</a>.</li>



<li>Jayud Global Logistics (NASDAQ:<a href="https://investorplace.com/stock-quotes/jyd-stock-quote/">JYD</a>) stock is heading more than 22% higher alongside heavy trading this morning.</li>



<li>U Power (NASDAQ:<a href="https://investorplace.com/stock-quotes/ucar-stock-quote/">UCAR</a>) shares are climbing over 20% <a href="https://www.nasdaq.com/press-release/uotta-technology-be-adopted-portuguese-national-taxi-association-drive">on a deal</a> with the Portuguese National Taxi Association.</li>



<li>Stitch Fix (NASDAQ:<a href="https://investorplace.com/stock-quotes/sfix-stock-quote/">SFIX</a>) stock is jumping more than 16% after <a href="https://finance.yahoo.com/news/stitch-fix-sfix-reports-q3-212003374.html">beating revenue estimates in fiscal Q3</a>.</li>



<li>Calidi Biotherapeutics (NYSEMKT:<a href="https://investorplace.com/stock-quotes/cldi-stock-quote/">CLDI</a>) shares are up over 14% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318374243&amp;type=PDF&amp;symbol=CLDI&amp;cdn=26f24d99b28a708fa7751a113b343d34&amp;companyName=Calidi+Biotherapeutics+Inc.&amp;formType=424B3&amp;formDescription=Prospectus+%5BRule+424%28b%29%283%29%5D&amp;dateFiled=2024-06-04">warrant exercise agreement</a>.</li>
</ol><h2>10 Top Losers</h2><ol></ol><ol><li>MicroAlgo (NASDAQ:<a href="https://investorplace.com/stock-quotes/mlgo-stock-quote/">MLGO</a>) stock is retreating more than 26% <a href="https://investorplace.com/2024/06/why-is-microalgo-mlgo-stock-up-162-today/">following a rally yesterday</a>.</li>



<li>SilverSun Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/ssnt-stock-quote/">SSNT</a>) shares are diving close to 23% on <a href="https://ca.finance.yahoo.com/news/insider-sale-ceo-mark-meller-070316512.html">a CEO stock sale</a>.</li>



<li>Sobr Safe (NASDAQ:<a href="https://investorplace.com/stock-quotes/sobr-stock-quote/">SOBR</a>) stock is pulling back over 21% <a href="https://investorplace.com/2024/06/why-is-sobr-safe-sobr-stock-up-83-today/">after yesterday&rsquo;s rally</a>.</li>



<li>Golden Heaven (NASDAQ:<a href="https://investorplace.com/stock-quotes/gdhg-stock-quote/">GDHG</a>) shares are tumbling more than 18% without any clear news this morning.</li>



<li>Fresh2 Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/fres-stock-quote/">FRES</a>) stock is taking an over 15% beating <a href="https://investorplace.com/2024/06/why-is-fresh2-group-fres-stock-up-31-today/">after climbing higher yesterday</a>.</li>



<li>Bone Biologics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bblg-stock-quote/">BBLG</a>) shares are sliding more than 14% despite a lack of news today.</li>



<li>Vast Renewables (NASDAQ:<a href="https://investorplace.com/stock-quotes/vste-stock-quote/">VSTE</a>) stock is dropping over 14% today.</li>



<li>ThredUp (NASDAQ:<a href="https://investorplace.com/stock-quotes/tdup-stock-quote/">TDUP</a>) shares are falling more than 12% on Wednesday.</li>



<li>ThermoGenesis (NASDAQ:<a href="https://investorplace.com/stock-quotes/thmo-stock-quote/">THMO</a>) stock is decreasing over 12% on an <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318372198&amp;type=PDF&amp;symbol=THMO&amp;cdn=06c6f2748734640b337b89e0d63957b3&amp;companyName=ThermoGenesis+Holdings+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-06-04">updated agreement with CBR Systems</a>.</li>



<li>MingZhu Logistics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ygmz-stock-quote/">YGMZ</a>) shares close out our pre-market stock movers down more than 12% today.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-june-5th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers for Wednesday morning as we check out all of the hottest news to start the day with!



Moving stocks this morning a partnerships, a public offering, clinical trial news and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Dermata Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/">DRMA</a>) stock is rocketing more than 123% alongside heavy pre-market trading.</li>



<li>Nuzee (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/">NUZE</a>) shares are soaring over 75% with strong early morning trading.</li>



<li>Hoth Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/hoth-stock-quote/">HOTH</a>) stock is surging more than 45% <a href="https://www.nasdaq.com/press-release/hoth-therapeutics-partners-lts-therapy-systems-accelerate-novel-alzheimers-treatment">on a new partnership</a> to develop its Alzheimer&rsquo;s treatment.</li>



<li>Allarity Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/allr-stock-quote/">ALLR</a>) shares are increasing over 44% after encouraging investors to <a href="https://finance.yahoo.com/news/allarity-encourages-shareholders-vote-reverse-100000785.html">vote for a reverse stock split</a>.</li>



<li>Regencell Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgc-stock-quote/">RGC</a>) stock is heading more than 33% higher alongside strong pre-market trading.</li>



<li>Pieris Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/pirs-stock-quote/">PIRS</a>) shares are rising over 28% after <a href="https://www.nasdaq.com/press-release/palvella-therapeutics-and-pieris-pharmaceuticals-announce-definitive-merger-agreement">announcing a merger agreement</a>.</li>



<li>Bone Biologics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bblg-stock-quote/">BBLG</a>) stock is jumping more than 23% with heavy early morning trading today.</li>



<li>NewGenIvf (NASDAQ:<a href="https://investorplace.com/stock-quotes/nivf-stock-quote/">NIVF</a>) shares are climbing over 22% after providing a <a href="https://www.nasdaq.com/press-release/newgenivf-provides-update-potential-reverse-merger-covirix-2024-07-23">reverse merger update</a>.</li>



<li>Perfect Moment (NYSEMKT:<a href="https://investorplace.com/stock-quotes/pmnt-stock-quote/">PMNT</a>) stock is getting a close to 19% boost after announcing a <a href="https://www.nasdaq.com/press-release/perfect-moment-teams-quiet-platforms-establish-distribution-center-us-2024-07-22">distribution center agreement</a>.</li>



<li>Catheter Precision (NYSEMKT:<a href="https://investorplace.com/stock-quotes/vtak-stock-quote/">VTAK</a>) shares are up more than 16% without any clear news this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Azitra&nbsp;(NYSEMKT:<a href="https://investorplace.com/stock-quotes/aztr-stock-quote/">AZTR</a>) stock is crashing over 73% but only <a href="https://investorplace.com/2024/07/why-is-azitra-aztr-stock-up-315-today/">after a massive rally yesterday</a>.</li>



<li>Conn&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/conn-stock-quote/">CONN</a>) shares are plummeting 28% on <a href="https://www.12newsnow.com/article/news/local/texas/conns-reportedly-planning-mass-closures/502-4db60564-6fdd-4ffa-ae26-899bec91f75c">reports of impending store closures</a>.</li>



<li>ATI Physical Therapy (NYSE:<a href="https://investorplace.com/stock-quotes/atip-stock-quote/">ATIP</a>) stock is diving more than 25% without any obvious news this morning.</li>



<li>Verastem (NASDAQ:<a href="https://investorplace.com/stock-quotes/vstm-stock-quote/">VSTM</a>) shares are tumbling over 25% on a <a href="https://finance.yahoo.com/news/verastem-oncology-announces-proposed-public-200500583.html">proposed public offering</a>.</li>



<li>Agape ATP (NASDAQ:<a href="https://investorplace.com/stock-quotes/atpc-stock-quote/">ATPC</a>) stock is taking an almost 24% beating after a rally yesterday.</li>



<li>AtlasClear (NYSEMKT:<a href="https://investorplace.com/stock-quotes/atch-stock-quote/">ATCH</a>) shares are sliding more than 22% despite a lack of news on Wednesday.</li>



<li>Sage Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/sage-stock-quote/">SAGE</a>) stock is dropping over 22% after reporting <a href="https://www.nasdaq.com/press-release/sage-therapeutics-and-biogen-announce-topline-results-phase-2-kinetic-2-study-sage">Phase 2 topline results</a>.</li>



<li>Volato (NYSEMKT:<a href="https://investorplace.com/stock-quotes/soar-stock-quote/">SOAR</a>) shares are decreasing more than 21% <a href="https://www.nasdaq.com/press-release/volato-updates-fractional-program-additional-differentiated-benefits-2024-07-23">after a recent rally</a>.</li>



<li>Chijet Motor (NASDAQ:<a href="https://investorplace.com/stock-quotes/cjet-stock-quote/">CJET</a>) stock is slipping over 19% following yesterday&rsquo;s rally.</li>



<li>Salarius Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/slrx-stock-quote/">SLRX</a>) shares close out our pre-market stock movers down more than 19% after a rally yesterday.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-july-24th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Bone Biologics to raise $2.1M through exercise of warrants

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
We have all of the biggest pre-market stock movers that traders need to know about on Friday morning!



Moving stocks this morning and more earnings reports, an acquisition deal, liquidation news and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Iteris (NASDAQ:<a href="https://investorplace.com/stock-quotes/iti-stock-quote/">ITI</a>) stock is rocketing more than 62% <a href="https://www.nasdaq.com/press-release/iteris-be-acquired-almaviva-335-million-2024-08-09">alongside an acquisition deal</a>.</li>



<li>Nauticus Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kitt-stock-quote/">KITT</a>) shares are soaring over 61% on a <a href="https://www.nasdaq.com/press-release/nauticus-robotics-enters-aquanaut-mark-2-testing-partnership-fau-2024-08-08">new testing partnership</a>.</li>



<li>FSD Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/huge-stock-quote/">HUGE</a>) stock is surging more than 37% alongside heavy pre-market trading.</li>



<li>Bone Biologics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bblg-stock-quote/">BBLG</a>) shares are gaining over 30% with the <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318504957&amp;type=PDF&amp;symbol=BBLG&amp;cdn=81b72413280ee9face7494c21cc37055&amp;companyName=Bone+Biologics+Corp&amp;formType=ARS&amp;formDescription=Annual+Report+to+Security+Holders&amp;dateFiled=2024-08-08">release of its annual report</a>.</li>



<li>Pitney Bowes (NYSE:<a href="https://investorplace.com/stock-quotes/pbi-stock-quote/">PBI</a>) stock is rising more than 30% on plans to <a href="https://finance.yahoo.com/news/pitney-bowes-liquidate-ecommerce-unit-221312483.html">liquidate its e-commerce unit</a>.</li>



<li>Marin Software (NASDAQ:<a href="https://investorplace.com/stock-quotes/mrin-stock-quote/">MRIN</a>) shares are increasing over 28% after <a href="https://www.businesswire.com/news/home/20240808458407/en/Marin-Software-Extends-Reach-with-Reddit-and-X-Support">adding support for Reddit and X</a>, previously called Twitter.</li>



<li>Clearmind Medicine (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmnd-stock-quote/">CMND</a>) stock is heading more than 27% higher without any clear news this morning.</li>



<li>Doximity (NYSE:<a href="https://investorplace.com/stock-quotes/docs-stock-quote/">DOCS</a>) shares are climbing over 27% on a <a href="https://www.marketwatch.com/story/doximity-shares-rally-after-beating-1q-earnings-guidance-expectations-b9ce97d7?mod=markets">fiscal Q1 earnings beat</a>.</li>



<li>Satellogic (NASDAQ:<a href="https://investorplace.com/stock-quotes/satl-stock-quote/">SATL</a>) stock is jumping more than 26% today.</li>



<li>Babcock &amp; Wilcox (NYSE:<a href="https://investorplace.com/stock-quotes/bw-stock-quote/">BW</a>) shares are up over 25% after releasing its <a href="https://www.businesswire.com/news/home/20240808728017/en/Babcock-Wilcox-Enterprises-Reports-Second-Quarter-2024-Results-Earnings-Growth-Driven-By-Strong-Operating-Performance">Q2 earnings report</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>AN2 Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/antx-stock-quote/">ANTX</a>) stock is diving more than 33% <a href="https://www.nasdaq.com/press-release/an2-therapeutics-provides-update-ebo-301-phase-2-3-study-evaluating-epetraborole">with a clinical trial update</a>.</li>



<li>American Vanguard (NYSE:<a href="https://investorplace.com/stock-quotes/avd-stock-quote/">AVD</a>) shares are tumbling over 29% with the <a href="https://www.nasdaq.com/press-release/american-vanguard-reports-q2-2024-results-2024-08-08">release of its latest earnings report</a>.</li>



<li>PubMatic (NASDAQ:<a href="https://investorplace.com/stock-quotes/pubm-stock-quote/">PUBM</a>) stock is taking a more than 27% beating on <a href="https://www.stocktitan.net/news/PUBM/pub-matic-announces-second-quarter-2024-financial-zmrbbq0dmfh8.html">missed Q2 revenue</a>.</li>



<li>Eventbrite (NYSE:<a href="https://investorplace.com/stock-quotes/eb-stock-quote/">EB</a>) shares are sliding over 23% alongside <a href="https://www.tipranks.com/news/company-announcements/eventbrite-announces-layoffs-and-welcomes-new-coo-cfo">layoffs and leadership changes</a>.</li>



<li>Beauty Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/skin-stock-quote/">SKIN</a>) stock is decreasing more than 22% after <a href="https://www.nasdaq.com/press-release/beautyhealth-reports-second-quarter-2024-financial-results-2024-08-08">posting its Q2 earnings report</a>.</li>



<li>Cutera (NASDAQ:<a href="https://investorplace.com/stock-quotes/cutr-stock-quote/">CUTR</a>) shares are dropping over 21% with its <a href="https://www.nasdaq.com/press-release/cuterar-announces-second-quarter-2024-financial-results-2024-08-08">latest earnings news</a>.</li>



<li>Microvast (NASDAQ:<a href="https://investorplace.com/stock-quotes/mvst-stock-quote/">MVST</a>) stock is falling more than 19% after releasing its <a href="https://ir.microvast.com/static-files/b376f438-a4e5-4a1a-ac22-a6107e450b24">Q2 2024 earnings</a>.</li>



<li>FiscalNote (NYSE:<a href="https://investorplace.com/stock-quotes/note-stock-quote/">NOTE</a>) shares are slipping over 18% after <a href="https://finance.yahoo.com/news/fiscalnote-holdings-inc-note-reports-231505554.html">posting a Q2 loss</a>.</li>



<li>Nerdy (NYSE:<a href="https://investorplace.com/stock-quotes/nrdy-stock-quote/">NRDY</a>) stock is dipping more than 18% after <a href="https://www.nasdaq.com/press-release/nerdy-announces-second-quarter-2024-financial-results-2024-08-08">releasing its Q2 earnings report</a>.</li>



<li>Five9 (NASDAQ:<a href="https://investorplace.com/stock-quotes/fivn-stock-quote/">FIVN</a>) shares close out our pre-market stock movers down over 15% with its <a href="https://www.nasdaq.com/press-release/five9-surpasses-1-billion-annual-revenue-run-rate-2024-08-08">most recent earnings report</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-aug-9th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Bone Biologics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bblg-stock-quote/">BBLG</a>) just reported results for the second quarter of 2024.<ul><li>Bone Biologics reported earnings per share of -67 cents. This was above the analyst estimate for EPS of -$1.39.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/bblg-stock-earnings-bone-biologics-for-q2-of-2024/">BBLG Stock Earnings: Bone Biologics Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BBLG Stock Earnings: Bone Biologics Beats EPS for Q2 2024

ALLR

ANTX

ARQT

ASNS

ATCH

ATIP

ATPC

AZTR

BBLG

CAPR

CJET

CMND

CONN

CUTR

DOCS

DRMA

FIVN

FRES

GDHG

HOTH

HSCS

HUGE

LSDI

MITQ

MLGO

MRIN

MVST

NDRA

NEPH

NIVF

NOTE

NTBL

NUZE

NVAX

PIRS

PMNT

PUBM

SAGE

SATL

SFIX

SKIN

SLRX

SOAR

SOBR

SSNT

TDUP

THMO

UCAR

VSTE

VSTM

VTAK

WKME

YGMZ

Press Releases

Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors

Bone Biologics Reports Progress With NB1 Clinical Program

Bone Biologics Announces Pricing of $2.0 Million Public Offering

Bone Biologics Announces Closing of $2.0 Million Public Offering

Bone Biologics Executives to be Interviewed in a "CEO Chat" by Zacks Small-Cap Research Analyst on June 20th

First Two Patients Treated in Pilot Clinical Study with Bone Biologics' NB1 Bone Graft Device in Spine Fusion

Actinium Pharmaceuticals (ATNM) Unveils Promising Advances in Targeted Radiotherapies for Cancer Treatment

Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Bone Biologics Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Comments

Bone Biologics

Bone Biologics (BBLG) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌